New Asthma Medication Saves Lives
A new asthma medication was researched in a Dutch trial. Benralizumab (brand name:? Fasenra) is given by injection. It is a monoclonal antibody directed at a blood component with the name eosinophils. It helps stabilize severe asthma as cytokine production of eosinophils ceases. The result is a remarkable clinical improvement of severe asthma patients. The only problem with Benralizumab treatment is the horrendous cost. One year treatment costs between 25,000 and 30,000 USD. This treatment is the only new treatment for asthma in the last 50 years.
--
2 个月Benralizumab has shown significant promise in treating severe asthma by targeting eosinophils, leading to clinical improvements for patients. However, its high cost, between $25,000 and $30,000 per year, creates a barrier to accessibility. While Benralizumab is a recent advancement, other biologics like dupilumab and mepolizumab have also contributed to progress in asthma treatment. Medical treatments and advancements should not be limited to a certain class of people; I believe access to better healthcare and treatment options should be available to everyone, regardless of their financial situation. Hopefully, the cost would be moderated for accessibility.